William P. Kane Jr. - 06 Feb 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Commercial Officer
Signature: /s/ Troy Ignelzi, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 06 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 07 Feb 2023, 17:16:51 UTC
Previous filing: 18 Aug 2021
Next filing: 29 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Award	$0	+17,656		$0.000000	17,656	06 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Stock Option (Right to Buy)	Award	$0	+29,937		$0.000000	29,937	06 Feb 2023	Common Stock	29,937	$192.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 6, 2024, subject to continued service through such dates.
F2	25% of this option shall vest on February 6, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.